Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

被引：0
作者：
Hojjat Ahmadzadehfar
Kambiz Rahbar
Richard P. Baum
Robert Seifert
Katharina Kessel
Martin Bögemann
Harshad R Kulkarni
Jingjing Zhang
Carolin Gerke
Rolf Fimmers
Clemens Kratochwil
Hendrik Rathke
Harun Ilhan
Johanna Maffey-Steffan
Mike Sathekge
Levent Kabasakal
Francisco Osvaldo Garcia-Perez
Kalevi Kairemo
Masha Maharaj
Diana Paez
Irene Virgolini
机构：
[1] University Hospital Bonn,Department of Nuclear Medicine
[2] Klinikum Westfalen,Department of Nuclear Medicine
[3] University Hospital Muenster,Department of Nuclear Medicine
[4] Zentralklinik Bad Berka,Center for Radiomolecular Precision Oncology
[5] University Hospital Münster,Department of Urology
[6] University of Bonn,Institute for Medical Biometry, Informatics and Epidemiology
[7] University Hospital Heidelberg,Department of Nuclear Medicine
[8] LMU,Department of Nuclear Medicine
[9] University Hospital Munich,Department of Nuclear Medicine
[10] Medical University Innsbruck,Department of Nuclear Medicine
[11] University of Pretoria & Steve Biko Academic Hospital,Department of Nuclear Medicine
[12] Istanbul University,Department of Nuclear Medicine and Molecular Imaging
[13] Instituto Nacional de Cancerología Mexico City,Department of Nuclear Medicine
[14] Docrates Cancer Center,Department of Nuclear Sciences and Applications
[15] Imaging and Therapy Centre,undefined
[16] Nuclear Medicine and Diagnostic Imaging Section,undefined
[17] IAEA,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2021年 / 48卷
关键词：
mCRPC; Radioligand therapy; Lu-PSMA; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：113 / 122
页数：9
相关论文
共 174 条
[1]  
Santoni M(2014)Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises J Biol Regul Homeost Agents 28 555-563
[2]  
Scarpelli M(1997)Prostate-specific membrane antigen expression in normal and malignant human tissues Clin Cancer Res 3 81-85
[3]  
Mazzucchelli R(2018)Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy Breast Cancer Res Treat 169 447-455
[4]  
Lopez-Beltran A(2010)Prostate specific membrane antigen-a target for imaging and therapy with radionuclides Discov Med 9 55-61
[5]  
Cheng L(2016)New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy Clin Cancer Res 22 9-15
[6]  
Cascinu S(2015)Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study EJNMMI Res 5 114-109
[7]  
Silver DA(2020)PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients Semin Nucl Med 50 98-265
[8]  
Pellicer I(2019)Efficacy and safety of (177)lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: first experience in west Asia-a prospective study World J Nucl Med 18 258-833
[9]  
Fair WR(2018)[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Lancet Oncol 19 825-22
[10]  
Heston WD(2019)Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression Clin Genitourin Cancer 17 15-926
12345678910